Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort .Randomized Phase Ⅱ Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-S ......